Ageing-related corpora veno-occlusive dysfunction in the rat is ameliorated by pioglitazone

BJU International

Volumn 100, Issue 4, 2007, Pages 867-874

  Kovanecz, Istvan ^a   Ferrini, Monica G ^a,b   Vernet, Dolores ^a   Nolazco, Gaby ^a   Rajfer, Jacob ^a,b   Gonzalez Cadavid, Nestor F ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Corporal fibrosis; Erectile dysfunction; PDE5 inhibitors; PPAR ; Smooth muscle

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RHO KINASE; TRANSFORMING GROWTH FACTOR BETA1;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; MALE; NONHUMAN; OXIDATIVE STRESS; PENIS; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VEIN OCCLUSION;

AGE FACTORS; ANIMALS; BLOTTING, WESTERN; COLLAGEN; FIBROSIS; IMMUNOHISTOCHEMISTRY; IMPOTENCE, VASCULOGENIC; MALE; OXIDATIVE STRESS; PENIS; PPAR GAMMA; RATS; RATS, INBRED F344; REACTIVE OXYGEN SPECIES; THIAZOLIDINEDIONES;

EID: 34548453726     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07070.x     Document Type: Article

References (51)

1. Rosen RC, Wing R, Schneider S, Gendrano N 3rd. Epidemiology of erectile dysfunction: the role of medical comorbidities and lifestyle factors. Urol Clin North Am 2005 32 : 403 17
2. Russell S, McVary KT. Lower urinary tract symptoms and erectile dysfunction: epidemiology and treatment in the aging man. Curr Urol Rep 2005 6 : 445 53
3. O'Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: The Massachusetts Male Aging Study (1987-2004). Exp Gerontol 2004 39 : 975 84
4. Rajfer J, Rosciszewski A, Mehringer M. Prevalence of corporeal venous leakage in impotent men. J Urol 1988 140 : 69 71
5. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol 1999 161 : 5 11
6. Davila HH, Rajfer J, Gonzalez-Cadavid NF. Corporal veno-occlusive dysfunction in the aging rat: evaluation by cavernosometry and cavernosography. Urology 2004 64 : 1261 6
7. Ferrini MG, Kovanecz I, Sanchez S et al. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis. Biol Reprod 2007 76 : 915 23
8. Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Pioglitazone prevents corporal veno-occlusive dysfunction (CVOD) in a rat model of type 2 diabetes mellitus. BJU Int 2006 98 : 116 24
9. Ferrini MG, Davila H, Kovanecz I, Sanchez S, Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of coporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 2006 68 : 429 35
10. Kovanecz I, Rambhatla A, Ferrini MG et al. Long term sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. J Sex Med 2007 4 (Suppl. 1 72 Abstract 29)
11. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004 171 : 771 4
12. Yaman O, Yilmaz E, Bozlu M, Anafarta K. Alterations of intracorporeal structures in patients with erectile dysfunction. Urol Int 2003 71 : 87 90
13. Ferrini M, Magee TR, Vernet D, Rajfer J, Gonzalez-Cadavid NF. Aging-related expression of inducible nitric oxide synthase (iNOS) and markers of tissue damage in the rat penis. Biol Reprod 2001 64 : 974 82
14. Garban H, Vernet D, Freedman A, Rajfer J, Gonzalez-Cadavid N. Effect of aging on nitric oxide-mediated penile erection in the rat. Am J Physiol 1995 268 : H467 75
15. User HM, Hairston JH, Zelner DJ, McKenna KE, McVary KT. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol 2003 169 : 1175 9
16. Leungwattanakij S, Bivalacqua TJ, Usta MF et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 2003 24 : 239 49
17. Bakircioglu ME, Sievert KD, Nunes L, Lau A, Lin CS, Lue TF. Decreased trabecular smooth muscle and caveolin-1 expression in the penile tissue of aged rats. J Urol 2001 166 : 734 8
18. Mills TM, Lewis RW, Wingard CJ, Linder AE, Jin L, Webb RC. Vasoconstriction, RhoA/Rho-kinase and the erectile response. Int J Impot Res 2003 15 (Suppl. 5 S20 4
19. Jin L, Burnett AL. RhoA/Rho-kinase in erectile tissue: mechanisms of disease and therapeutic insights. Clin Sci (Lond) 2006 110 : 153 65
20. El Melegy NT, Ali ME, Awad EM. Plasma levels of endothelin-1, angiotensin II, nitric oxide and prostaglandin E in the venous and cavernosal blood of patients with erectile dysfunction. BJU Int 2005 96 : 1079 86
21. Wakino S, Hayashi K, Kanda T et al. Peroxisome proliferator-activated receptor γ ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res 2004 95 : e45 55
22. Chang Y, Ceacareanu B, Dixit M, Sreejayan N, Hassid A. Nitric oxide-induced motility in aortic smooth muscle cells: role of protein tyrosine phosphatase SHP-2 and GTP-binding protein Rho. Circ Res 2002 91 : 390 7
23. Gao DF, Niu XL, Hao GH et al. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPARγ in vascular fibrosis. Biochem Pharmacol 2007 73 : 185 97
24. Roberts AW, Thomas A, Rees A, Evans M. Peroxisome proliferator-activated receptor-γ agonists in atherosclerosis: current evidence and future directions. Curr Opin Lipidol 2003 14 : 567 73
25. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006 113 : 867 75
26. Horio T, Suzuki M, Takamisawa I et al. Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am J Hypertens 2005 18 : 1626 30
27. Ferrini MG, Davila HH, Valente EG, Gonzalez-Cadavid NF, Rajfer J. Aging-related induction of inducible nitric oxide synthase is vasculo-protective in the arterial media. Cardiovascular Res 2004 61 : 796 805
28. Ferrini MG, Vernet D, Magee TR et al. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002 6 : 283 94
29. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int 2003 91 : 830 8
30. Artaza JN, Bhasin S, Magee TR et al. Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2): mesenchymal multipotent cells. Endocrinology 2005 146 : 3547 57
31. Campbell IW. The clinical significance of PPARγ agonism. Curr Mol Med 2005 5 : 349 63
32. Granberry MC, Fonseca VA. Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs 2005 5 : 201 9
33. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004 27 : 982 91
34. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. l-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003 9 : 229 44
35. Da Ros R, Assaloni R, Ceriello A. The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabet Med 2004 21 : 1249 52
36. Sung B, Park S, Yu BP, Chung HY. Amelioration of age-related inflammation and oxidative stress by PPARγ activator: suppression of NF-κB by 2,4-thiazolidinedione. Exp Gerontol 2006 41 : 590 9
37. Ye P, Zhang XJ, Wang ZJ, Zhang C. Effect of aging on the expression of peroxisome proliferator-activated receptor γ and the possible relation to insulin resistance. Gerontology 2006 52 : 69 75
38. Sung B, Park S, Yu BP, Chung HY. Modulation of PPAR in aging, inflammation, and calorie restriction. J Gerontol A Biol Sci Med Sci 2004 59 : 997 1006
39. Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM. PPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 2006 350 : 385 91
40. Yang L, Chan CC, Kwon OS et al. Regulation of peroxisome proliferator-activated receptor-γ in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2006 291 : G902 11
41. Jaster R, Lichte P, Fitzner B et al. Peroxisome proliferator-activated receptor γ overexpression inhibits pro-fibrogenic activities of immortalised rat pancreatic stellate cells. J Cell Mol Med 2005 9 : 670 82
42. Burgess HA, Daugherty LE, Thatcher TH et al. PPARγ agonists inhibit TGFβ induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005 288 : L1146 53
43. Peng Y, Liu H, Liu F, Liu Y, Li J, Chen X. Troglitazone inhibits synthesis of transforming growth factor-β1 and reduces matrix production in human peritoneal mesothelial cells. Nephrology (Carlton) 2006 11 : 516 23
44. Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC. PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 2006 21 : 2399 405
45. Wang K, Zhou Z, Zhang M et al. Peroxisome proliferator-activated receptor γ down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 2006 317 : 37 43
46. Bruemmer D, Law RE. Thiazolidinedione regulation of smooth muscle cell proliferation. Am J Med 2003 115 (Suppl. 8A 87S 92S
47. Heppner TJ, Bonev AD, Eckman DM, Gomez MF, Petkov GV, Nelson MT. Novel PPARγ agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. Pharmacology 2005 73 : 15 22
48. Goya K, Sumitani S, Otsuki M et al. The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells. J Diabetes Complications 2006 20 : 336 42
49. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005 46 : 773 8
50. Sidhu JS, Cowan D, Kaski JC. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 2004 94 : 151 6
51. Magee TR, Kovanecz I, Davila HH, et al. Antisense and short hairpin RNA (shRNA) constructs targeting PIN (Protein Inhibitor of NOS) ameliorate aging-related erectile dysfunction in the rat. J Sex Med 2007 4 : 633 43